News & Media :: Vedanta Biosciences, Inc.

May 24, 2022

Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting

Recent News

Apr 13, 2022

Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results

Oct 14, 2021

Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary

Oct 5, 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Jul 21, 2021

Vedanta Biosciences Completes $68 Million Series D Financing

View All News View All Press Releases